These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
961 related articles for article (PubMed ID: 29037218)
21. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662 [TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F; Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630 [TBL] [Abstract][Full Text] [Related]
23. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155 [TBL] [Abstract][Full Text] [Related]
24. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
25. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388 [TBL] [Abstract][Full Text] [Related]
26. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538 [TBL] [Abstract][Full Text] [Related]
27. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
28. BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? Price TJ; Beeke C; Townsend AR; Lo L; Amitesh R; Padbury R; Roder D; Maddern G; Moore J; Karapetis C Mol Diagn Ther; 2016 Feb; 20(1):75-82. PubMed ID: 26714964 [TBL] [Abstract][Full Text] [Related]
29. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672 [TBL] [Abstract][Full Text] [Related]
30. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839 [TBL] [Abstract][Full Text] [Related]
31. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
32. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
33. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476 [TBL] [Abstract][Full Text] [Related]
34. Negative Hyperselection of Patients With Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295 [TBL] [Abstract][Full Text] [Related]
35. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. Amrane K; le Pennec R; Schick U; Metges JP; Abgral R Clin Nucl Med; 2020 Sep; 45(9):707-708. PubMed ID: 32657876 [TBL] [Abstract][Full Text] [Related]
36. BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer. Owaki S; Mori Y; Nakai S; Maeda H; Imazu M; Tomita Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Hirano A; Kimura Y; Tsuchida K; Kataoka H Intern Med; 2024 Jul; 63(14):1995-1999. PubMed ID: 37981300 [TBL] [Abstract][Full Text] [Related]
37. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V; Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756 [TBL] [Abstract][Full Text] [Related]
38. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581 [TBL] [Abstract][Full Text] [Related]
40. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]